547 related articles for article (PubMed ID: 8612485)
1. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway.
Hedlund TE; Moffatt KA; Miller GJ
Endocrinology; 1996 May; 137(5):1554-61. PubMed ID: 8612485
[TBL] [Abstract][Full Text] [Related]
2. Actions of vitamin D3, analogs on human prostate cancer cell lines: comparison with 1,25-dihydroxyvitamin D3.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1995 Jan; 136(1):20-6. PubMed ID: 7530193
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D receptor expression is required for growth modulation by 1 alpha,25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31.
Hedlund TE; Moffatt KA; Miller GJ
J Steroid Biochem Mol Biol; 1996 Jun; 58(3):277-88. PubMed ID: 8836163
[TBL] [Abstract][Full Text] [Related]
4. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha,25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer.
Chen TC; Schwartz GG; Burnstein KL; Lokeshwar BL; Holick MF
Clin Cancer Res; 2000 Mar; 6(3):901-8. PubMed ID: 10741714
[TBL] [Abstract][Full Text] [Related]
5. Genistein potentiates the growth inhibitory effects of 1,25-dihydroxyvitamin D3 in DU145 human prostate cancer cells: role of the direct inhibition of CYP24 enzyme activity.
Swami S; Krishnan AV; Peehl DM; Feldman D
Mol Cell Endocrinol; 2005 Sep; 241(1-2):49-61. PubMed ID: 15955619
[TBL] [Abstract][Full Text] [Related]
6. Antiproliferative responses to two human colon cancer cell lines to vitamin D3 are differently modified by 9-cis-retinoic acid.
Kane KF; Langman MJ; Williams GR
Cancer Res; 1996 Feb; 56(3):623-32. PubMed ID: 8564982
[TBL] [Abstract][Full Text] [Related]
7. Vitamin D receptor expression, 24-hydroxylase activity, and inhibition of growth by 1alpha,25-dihydroxyvitamin D3 in seven human prostatic carcinoma cell lines.
Miller GJ; Stapleton GE; Hedlund TE; Moffat KA
Clin Cancer Res; 1995 Sep; 1(9):997-1003. PubMed ID: 9816072
[TBL] [Abstract][Full Text] [Related]
8. The anti-proliferative effects of 1alpha,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression.
Campbell MJ; Gombart AF; Kwok SH; Park S; Koeffler HP
Oncogene; 2000 Oct; 19(44):5091-7. PubMed ID: 11042697
[TBL] [Abstract][Full Text] [Related]
9. Vitamin D and systemic cancer: is this relevant to malignant melanoma?
Osborne JE; Hutchinson PE
Br J Dermatol; 2002 Aug; 147(2):197-213. PubMed ID: 12174089
[TBL] [Abstract][Full Text] [Related]
10. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity.
Ly LH; Zhao XY; Holloway L; Feldman D
Endocrinology; 1999 May; 140(5):2071-6. PubMed ID: 10218956
[TBL] [Abstract][Full Text] [Related]
11. Regulation of the murine renal vitamin D receptor by 1,25-dihydroxyvitamin D3 and calcium.
Healy KD; Zella JB; Prahl JM; DeLuca HF
Proc Natl Acad Sci U S A; 2003 Aug; 100(17):9733-7. PubMed ID: 12900504
[TBL] [Abstract][Full Text] [Related]
12. Evidence for coordinated regulation of osteoblast function by 1,25-dihydroxyvitamin D3 and parathyroid hormone.
van Leeuwen JP; Birkenhäger JC; van den Bemd GC; Pols HA
Biochim Biophys Acta; 1996 Jun; 1312(1):54-62. PubMed ID: 8679716
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines.
Skowronski RJ; Peehl DM; Feldman D
Endocrinology; 1993 May; 132(5):1952-60. PubMed ID: 7682937
[TBL] [Abstract][Full Text] [Related]
14. Requirements for induction of vitamin D-mediated gene regulation in normal human B lymphocytes.
Morgan JW; Morgan DM; Lasky SR; Ford D; Kouttab N; Maizel AL
J Immunol; 1996 Oct; 157(7):2900-8. PubMed ID: 8816395
[TBL] [Abstract][Full Text] [Related]
15. Antagonistic action of novel 1alpha,25-dihydroxyvitamin D3-26, 23-lactone analogs on differentiation of human leukemia cells (HL-60) induced by 1alpha,25-dihydroxyvitamin D3.
Miura D; Manabe K; Ozono K; Saito M; Gao Q; Norman AW; Ishizuka S
J Biol Chem; 1999 Jun; 274(23):16392-9. PubMed ID: 10347199
[TBL] [Abstract][Full Text] [Related]
16. Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells.
Zhao X; Feldman D
Endocrinology; 1993 Apr; 132(4):1808-14. PubMed ID: 8384998
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of 1,25-dihydroxyvitamin D3 stimulated osteocalcin gene transcription by tumor necrosis factor-alpha: structural determinants within the vitamin D response element.
Kuno H; Kurian SM; Hendy GN; White J; deLuca HF; Evans CO; Nanes MS
Endocrinology; 1994 Jun; 134(6):2524-31. PubMed ID: 8194478
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling in melanoma cells.
Sertznig P; Dunlop T; Seifert M; Tilgen W; Reichrath J
Anticancer Res; 2009 Sep; 29(9):3647-58. PubMed ID: 19667161
[TBL] [Abstract][Full Text] [Related]
19. Demonstration that 1 beta,25-dihydroxyvitamin D3 is an antagonist of the nongenomic but not genomic biological responses and biological profile of the three A-ring diastereomers of 1 alpha,25-dihydroxyvitamin D3.
Norman AW; Bouillon R; Farach-Carson MC; Bishop JE; Zhou LX; Nemere I; Zhao J; Muralidharan KR; Okamura WH
J Biol Chem; 1993 Sep; 268(27):20022-30. PubMed ID: 8397195
[TBL] [Abstract][Full Text] [Related]
20. Consequences of vitamin D receptor regulation for the 1,25-dihydroxyvitamin D3-induced 24-hydroxylase activity in osteoblast-like cells: initiation of the C24-oxidation pathway.
Staal A; van den Bemd GJ; Birkenhäger JC; Pols HA; van Leeuwen JP
Bone; 1997 Mar; 20(3):237-43. PubMed ID: 9071474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
